Search Results - dimiter+dimitrov

23 Results

Sort By:

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Abstract: No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Tianlei Ying, Tina Ju, Kwok Yuen

Keywords(s): ANTIBODY, CORONAVIRUS, MERs, middle east respiratory syndrome

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Human and Improved Murine Monoclonal Antibodies Against CD22

Abstract: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown...

Published: 8/14/2024 | Inventor(s): Dimiter Dimitrov, Xiaodong Xiao, Ira Pastan

Keywords(s): antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma

Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao

Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents

Abstract: The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology. The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Qi Zhao, Zhongyu Zhu

Keywords(s): Dimitrov, IGF-I, IGF-II, insulin-like growth factor, Monoclonal Antibody

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer

Abstract: The tumor microenvironment consists of a heterogenous population of cells which includes tumor cells and tumor-associated stroma cells (TASCs). The TASCs promote tumor angiogenesis, proliferation, invasion and metastasis. Because stroma cells are found in both healthy and cancerous tissue, targeting the tumor stroma has been difficult due...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire Ubani, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), ANTXR1, TEM8, Tumor Microenvironment, Tumor Stroma

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy. sCD4 is also known to interact...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): CD4, Dimitrov, fusion protein, HIV-1, Single Domain Antibodies (sdAb)

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

HIV-1 Therapeutic Inhibits Viral Entry

Abstract: Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Prabakaran Ponraj

Keywords(s): CD4, entry inhibitor, HIV, MHCII, soluble expression

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma

Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov

Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus,...

Published: 4/8/2024 | Inventor(s): Rimas Orentas, Nirali Shah, Ira Pastan, Crystal Mackall, Dimiter Dimitrov

Keywords(s): Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

1 2 3